SciSparc Ltd.
SPRCNasdaq
$5.00
↓ -6.7%Jul 17 close · end-of-day
Price
1Y↓ -92.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
SciSparc Ltd. develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation. SCi-160 for the. treatment of pain; SCII-210 for the. treatment of autism spectrum disorder and epilepsy. The company was formerly known as Therapix Biosciences.
- CEO
- Oz Adler
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Website
- scisparc.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 15, 2026
- 5d agoNeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndromefinance.yahoo.com
- 5d agoSciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndromefinance.yahoo.com
Jun 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.